Tia Portal V11 Sp2 Crack.epub
Sabelia Ewings
I began dreaming about those vans. In certain dreams, a van paused, finally, in front of me. The passenger window lowered. A delicious scent poured forth from the inside. Time slowed down. The driver of the van leaned out of her window and shook a piece of candy. Each movement of her arm took an hour. I stood there, uncertain of what to do, hoping the decision would be made for me: that either the van would drive away, or the hand would reach down, grab my corduroy dress, and pull me in.
Several girls who went to that party, not portal girls, but girls like me, jumped off of their own roofs in the weeks that followed. I would have tried it, too, if it worked. That fall, I first found blood on my underwear, and right away I sensed a change in the air, a closing off, and a new feeling of disgust. For a time, it was like all the portals went away.
I returned to Illinois with my two kids, to the house in which I grew up. It was tornado season. There were many more tornados than I remember. Numerous afternoons that first summer were spent huddled in the basement beside the holiday boxes, my mom clutching onto her flashlight that she occasionally shined into each of our faces, making sure we were still there.
After a three-day stay in the hospital, my mom returned home. There was a bag attached to her neck via a plastic tube. My dad drained the bag for her every day in the powder room. He and my mother began taking slow afternoon strolls, not long, sometimes only to the end of the block and back, or on other days going a little further and turning around at the park. They went even when the storm sirens were wailing and the sky looked sick. My dad wore a pair of binoculars around his neck while my mom held her notebook. On their initial walk, they spotted two portals glinting in the distance. On their second walk, they saw five. One of the worlds through the portal looked very soft, my dad said. Like if you took a step onto that world, you would sink right through to its very center. One of the worlds contained all the colors of a sunrise.
My mother never recovered from that surgery. Last week, she barely had the energy to get out of bed. Her daily walk consisted of strolling from her bedroom into the kitchen with my father at her side. Her portals have begun to line the hallway of this house. They appear in the windows to the kitchen. I would have gone through any one of them with her.
At the bottom of her marker board, she drew a complicated shape in outline with numerous sharp angles. It could have been a maze. It could have been creeping vines, the kind that strangle you in your sleep, or else the kind that grow a single orange flower. There seemed to be no beginning and no end to the object she drew. I think it had a heart in its center, though my mother has never been able to draw objects accurately, so it might not have been a heart. Then the timer on the microwave went off, reminding me to pick my children up at the bus stop. It was a windy day and the squirrels stayed away from me.
Lactulose is a versatile pharmaceutical agent helpful in preventing and treating clinical portal-systemic encephalopathy. By primarily targeting the reduction of intestinal production and absorption of ammonia, this drug addresses the root cause of the condition. Beyond its established efficacy in portal-systemic encephalopathy, lactulose has garnered recognition as a potential therapeutic solution for subacute clinical encephalopathy.
Moreover, its application extends to managing chronic constipation, where the combined impact of its osmotic effect and modulation of intestinal motility contributes to its therapeutic effectiveness. This activity encompasses the pharmacological aspects of lactulose, detailing its mechanisms of action, potential adverse events, eligible patient populations, contraindications, and the essential role of the interprofessional team in the meticulous management of lactulose therapy.
Objectives:
- Identify the indications for lactulose therapy based on patient presentations and medical history.Screen patients for contraindications or precautions to lactulose use, considering factors such as galactosemia, gastrointestinal obstruction, and electrolyte imbalances.Apply knowledge of potential adverse events associated with lactulose, such as flatulence, abdominal discomfort, and electrolyte disturbances, and develop strategies to mitigate or manage them.Develop effective communication with patients about the benefits, risks, and proper use of lactulose, ensuring their understanding and adherence to the prescribed regimen.
Lactulose is used to prevent and treat clinical portal-systemic encephalopathy and was first used in clinical practice in 1966.[1] The drug's chief mechanism of action is to decrease the intestinal production and absorption of ammonia. Lactulose has also gained popularity as a potential therapeutic agent for managing subacute clinical encephalopathy.[2] Lactulose is also a laxative for treating chronic constipation and has undergone study as early as the 1960s.[3] Lactulose's osmotic effect and its effect on intestinal motility receive credit for its therapeutic efficacy.[4]
Lactulose can be helpful as a third-line agent for chronic constipation once lifestyle modifications and increasing fiber intake have failed.[4] Because of lactulose's ability to significantly reduce intestinal transit time, it can also reduce deoxycholic acid's hypersaturation, thereby inhibiting cholesterol stone formation.[5] Recent studies have looked at lactulose for developing novel anticancer therapeutic agents due to its ability to bind to galectins (a carbohydrate-binding protein that plays a role in tumor progression).[6]
Lactulose, or 1,4-β-galactoside-fructose, is a non-absorbable synthetic disaccharide made of galactose and fructose.[7] The human small intestinal mucosa does not have the enzymes to split lactulose, so lactulose reaches the large bowel unchanged. Lactulose is metabolized in the colon by colonic bacteria to monosaccharides and then to volatile fatty acids, hydrogen, and methane. Lactulose reduces intestinal ammonia production and absorption in 3 ways.
First, the colonic metabolism of sugars causes a laxative effect via increased intraluminal gas formation and osmolality, which reduces transit time and intraluminal pH. This laxative effect is also beneficial for constipation.[7]
Next, lactulose promotes increased ammonia uptake by colonic bacteria, which utilize the trapped colonic ammonia as a nitrogen source for protein synthesis. The reduction of intestinal pH facilitates this process, which favors the conversion of ammonia (NH3) the gut bacteria produces to ammonium (NH4+), an ionized form of the molecule that cannot cross biological membranes.[8][9][10]
Finally, lactulose also causes a reduction in intestinal production of ammonia. The acidic pH destroys urease-producing bacteria involved in the production of ammonia. The unabsorbed disaccharide also inhibits intestinal glutaminase activity, which blocks the intestinal uptake of glutamine and its metabolism to ammonia.
Although a variety of mechanisms of action of lactulose that limit the production and absorption of ammonia in the gut, as explained above, have been reported, other laxatives could probably have the same effects with better tolerability. Lactulose originally received FDA approval in the USA in 1977, but there are concerns regarding the adequacy of data to support the drug's efficacy. As lactulose is believed to be an effective therapy for hepatic encephalopathy, it cannot be ethically withheld from patients needing treatment. Thus, conducting human investigation review board-approved placebo-controlled trials in the US to confirm or refute the efficacy of lactulose remains difficult.
Although the oral route (as a syrup) has been the standard mode of administration for the past several decades, it is also effective as a rectal enema.[1][11] Most of these studies were comparisons between lactulose/lactitol enemas and placebo. The few studies that have compared oral vs rectal lactulose have demonstrated inconclusive findings in the long term.[12]
Lactitol, a second-generation disaccharide, is a crystalline powder unavailable in the United States. Lactitol is equally efficacious but better tolerated than lactulose and is usually prescribed at a dose of 10 to 90 g/d to cause 2 soft bowel movements per day. At present, the most commonly used regimens of lactulose are as follows.[13]
For acute hepatic encephalopathy, a common option is to administer a bolus of 45 mL (30 g) and repeat the dose hourly until the first bowel movement. Once the episode of encephalopathy has subsided, the dose can be titrated to achieve 2 or 3 soft bowel movements daily.
This mode is preferred if there is any aspiration risk via the oral route. The preferred route is to administer 300 mL in 700 mL of water and have it retained in the colon for an hour, repeated every 2 hours until the episode resolves. The patient should be in the lateral recumbent position to optimize intestinal distribution.
Pregnancy considerations: Lactulose is a pregnancy category B drug. Based on reproduction studies conducted in mice, rats, and rabbits at 2 or 4 times the usual human oral dose, there has been no evidence of impaired fertility or fetal harm due to lactulose. However, there are no adequate and well-controlled studies conducted in pregnant women. Therefore, this drug should be used during pregnancy only if needed clearly.[14][15]
Breastfeeding considerations: Whether lactulose is excreted in human milk is unknown. However, many drugs are excreted in human milk, so it would be advisable to exercise caution when lactulose is administered to a breastfeeding woman.
Pediatric patients: There is very little information available on the use of lactulose in pediatric patients. In adult studies, the main goal is to produce 2 to 3 soft stools daily. On that basis, the recommended initial daily oral dose in infants would be 2.5 to 10 mL in divided doses. The daily dose of 0 to 90 mL is recommended for older children and adolescents. If this initial dose causes diarrhea, the dose should be lowered immediately. If diarrhea persists, lactulose treatment should be discontinued.[16][17]
b1e95dc632